Free Trial
OTCMKTS:OPHLF

Ono Pharmaceutical (OPHLF) Stock Price, News & Analysis

Ono Pharmaceutical logo
$9.33 0.00 (0.00%)
As of 06/27/2025

About Ono Pharmaceutical Stock (OTCMKTS:OPHLF)

Key Stats

Today's Range
$9.33
$9.33
50-Day Range
$9.33
$12.75
52-Week Range
$9.20
$16.05
Volume
N/A
Average Volume
1,228 shs
Market Capitalization
$4.38 billion
P/E Ratio
13.33
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Receive OPHLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

OPHLF Stock News Headlines

New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Nectar Classic Hybrid Mattress review 2024
The best Plank mattresses of 2024, tested and reviewed
See More Headlines

OPHLF Stock Analysis - Frequently Asked Questions

Ono Pharmaceutical's stock was trading at $9.60 at the beginning of 2025. Since then, OPHLF stock has decreased by 2.8% and is now trading at $9.33.
View the best growth stocks for 2025 here
.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) issued its earnings results on Monday, February, 3rd. The company reported $0.21 earnings per share for the quarter. Ono Pharmaceutical had a trailing twelve-month return on equity of 6.20% and a net margin of 10.24%.

Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
2/03/2025
Today
6/30/2025
Next Earnings (Estimated)
7/28/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
OTCMKTS:OPHLF
Employees
3,853
Year Founded
N/A

Profitability

Trailing P/E Ratio
13.33
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$330.31 million
Pretax Margin
12.19%

Debt

Sales & Book Value

Annual Sales
$3.20 billion
Cash Flow
$1.08 per share
Price / Cash Flow
8.66
Book Value
$11.07 per share
Price / Book
0.84

Miscellaneous

Free Float
N/A
Market Cap
$4.38 billion
Optionable
Not Optionable
Beta
0.52
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:OPHLF) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners